# CG Oncology, Inc.: overview

CGON · Nasdaq · CIK 1991792 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cgon.md) · [Financials](/companies/cgon/financials.md) · [Filings](/companies/cgon/filings.md) · [Insiders](/companies/cgon/insiders.md)

Latest reported revenue: [$1.2m](/filings/0001193125-26-336918.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-336918).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001193125-25-283000.md) | [0.5 d](/filings/0001193125-26-079498.md) | [0.1](/filings/0001193125-26-214669.md) | [0.0](/filings/0001193125-26-336918.md) | [1.7](/filings/0001193125-25-283000.md) | [2.3 d](/filings/0001193125-26-079498.md) | [1.1](/filings/0001193125-26-214669.md) | [1.2](/filings/0001193125-26-336918.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(65802.3%)](/filings/0001193125-25-283000.md) | [(8344.1%) d](/filings/0001193125-26-079498.md) | [(81161.5%)](/filings/0001193125-26-214669.md) | not reported | [(3069.0%)](/filings/0001193125-25-283000.md) | [(2097.3%) d](/filings/0001193125-26-079498.md) | [(6130.1%)](/filings/0001193125-26-214669.md) | [(7467.7%)](/filings/0001193125-26-336918.md) |
| Net margin | % | [(47453.5%)](/filings/0001193125-25-283000.md) | [(6973.2%) d](/filings/0001193125-26-079498.md) | [(66253.8%)](/filings/0001193125-26-336918.md) | not reported | [(2629.5%)](/filings/0001193125-25-283000.md) | [(1779.0%) d](/filings/0001193125-26-079498.md) | [(5558.8%)](/filings/0001193125-26-336918.md) | [(6832.8%)](/filings/0001193125-26-336918.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001193125-25-283000.md) | not reported | [(0.45)](/filings/0001193125-26-214669.md) | [(0.54)](/filings/0001193125-26-336918.md) | [(0.57)](/filings/0001193125-25-283000.md) | not reported | [(0.71)](/filings/0001193125-26-214669.md) | [(0.90)](/filings/0001193125-26-336918.md) |
| Free cash flow | $m | [(15.9) d](/filings/0001193125-25-283000.md) | [(20.9) d](/filings/0001193125-26-079498.md) | [(29.3)](/filings/0001193125-26-214669.md) | [(28.0) d](/filings/0001193125-26-336918.md) | [(39.0) d](/filings/0001193125-25-283000.md) | [(36.2) d](/filings/0001193125-26-079498.md) | [(57.2)](/filings/0001193125-26-214669.md) | [(46.9) d](/filings/0001193125-26-336918.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001193125-26-079498.md) | [1.1](/filings/0001193125-26-079498.md) | [4.0](/filings/0001193125-26-079498.md) |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | [(27180.9%)](/filings/0001193125-26-079498.md) | [(10067.3%)](/filings/0001193125-26-079498.md) | [(4722.1%)](/filings/0001193125-26-079498.md) |
| Net margin | % | [(23827.0%)](/filings/0001193125-26-079498.md) | [(7729.5%)](/filings/0001193125-26-079498.md) | [(3985.0%)](/filings/0001193125-26-079498.md) |
| Diluted EPS | $ per share | [(15.65)](/filings/0001193125-26-079498.md) | [(1.41)](/filings/0001193125-26-079498.md) | [(2.08)](/filings/0001193125-26-079498.md) |
| Free cash flow | $m | not reported | [(78.9)](/filings/0001193125-26-079498.md) | [(132)](/filings/0001193125-26-079498.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cgon/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $605.0m | 8,514,590 |  | Added +1,529,782 |
| [Decheng Capital LLC](/funds/2010850.md) | 2026-06-30 | $452.7m | 6,371,669 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $444.5m | 6,256,288 |  | Added +1,192,108 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $378.3m | 5,324,751 |  | Reduced −46,481 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $295.7m | 4,161,493 |  | Added +396,649 |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $260.8m | 3,670,206 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $246.2m | 3,465,197 |  | Added +370,099 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $244.2m | 3,437,590 |  | Added +790,536 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $235.7m | 3,316,793 |  | Added +283,168 |
| [Foresite Capital Management VI LLC](/funds/2013341.md) | 2026-06-30 | $168.4m | 2,369,574 |  | Added +148,100 |

## Recent filings

[All 240 filings](/companies/cgon/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 12:45 ET | [10-Q](/filings/0001193125-26-336918.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336918 |
| 2026-08-06 | 12:30 ET | [8-K](/filings/0001193125-26-336886.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-336886 |
| 2026-06-08 | 20:02 ET | [8-K](/filings/0001193125-26-261670.md) | 5.07 Shareholder vote results | 0001193125-26-261670 |
| 2026-05-26 | 12:00 ET | [8-K](/filings/0001193125-26-237908.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-237908 |
| 2026-05-08 | 20:15 ET | [10-Q](/filings/0001193125-26-214669.md) | Quarterly report, period 2026-03-31 | 0001193125-26-214669 |
| 2026-05-08 | 12:45 ET | [8-K](/filings/0001193125-26-213440.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213440 |
| 2026-04-24 | 20:30 ET | [DEF 14A](/filings/0001193125-26-177395.md) | Proxy statement, period 2026-04-23 | 0001193125-26-177395 |
| 2026-04-13 | 12:30 ET | [8-K](/filings/0001193125-26-152044.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-152044 |
| 2026-02-27 | 14:00 ET | [10-K](/filings/0001193125-26-079498.md) | Annual report, period 2025-12-31 | 0001193125-26-079498 |
| 2026-02-27 | 13:45 ET | [8-K](/filings/0001193125-26-079452.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-079452 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-079498.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a9c442d6-f9f7-499e-9d78-f7556725fa57)

## About the filer

- CIK: 1991792
- Tickers: CGON
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.